Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has announcements × Ann Arbor Stage IIB Hodgkin Lymphoma × prednylidene × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Burkitt Lymphoma 1 Ann Arbor Stage IIB Hodgkin Lymphoma 1

Interventions

prednylidene 1 exifone 1 deltacortene 1 Vincristine 1 Prednisone 1 Methylprednisolone 1 Medrol Veriderm 1 Etoposide 1 Doxorubicin 1 Cyclophosphamide 1 Brentuximab Vedotin 1 Bleomycin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02166463 2026-03-18

Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma

National Cancer Institute (NCI)

Phase 3 Active not recruiting

600 enrolled 14 charts 1 FDA

Ann Arbor Stage IIB Hodgkin Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡